Non-alcoholic fatty liver disease in type 2 diabetes:Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies

作     者：Subhodip Pramanik Partha Pal Sayantan Ray 

作者机构：Department of EndocrinologyNeotia Getwel Multispecialty HospitalSiliguri 734010West BengalIndia Department of Medical GastroenterologyAsian Institute of GastroenterologyHyderabad 500082India Department of EndocrinologyAll India Institute of Medical SciencesBhubaneswarBhubaneswar 751019OdishaIndia 

出 版 物：《World Journal of Methodology》 (世界方法学杂志)

年 卷 期：2024年第14卷第2期

页      面：38-50页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Non-alcoholic fatty liver disease Type 2 diabetes Evidence PPAR agonists Incretin-based therapies 

摘      要：Nonalcoholic fatty liver disease(NAFLD)is a global epidemic,affecting more than half of the people living with type 2 diabetes(T2D).The relationship between NAFLD and T2D is bidirectional and the presence of one perpetuates the other,which significantly increases the hepatic as well as extrahepatic *** recently,there was no approved pharmacological treatment for NAFLD/nonalcoholic steatohepatitits(NASH).However,there is evidence that drugs used for diabetes may have beneficial effects on *** sensitizers acting through peroxisome proliferator-activated receptor(PPAR)modulation act on multiple levels of NAFLD ***(PPARγ agonist)and saroglitazar(PPARα/γagonist)are particularly beneficial and recommended by several authoritative bodies for treating NAFLD in T2D,although data on biopsyproven NASH are lacking with the *** data on elafibanor(PPARα/δ agonist)and Lanifibranor(pan PPAR agonist)are *** the other hand,incretin therapies based on glucagon-like peptide-1(GLP-1)receptor agonists(GLP-1RA)and dual-and triple-hormone receptor co-agonists reported impressive weight loss and may have anti-inflammatory and antifibrotic ***-1 RAs have shown beneficial effects on NAFLD/NASH and more studies on potential direct effects on liver function by dual-and triple-agonists are ***,the long-term safety of these therapies in NAFLD needs to be *** efforts among healthcare providers such as primary care doctors,hepatologists,and endocrinologists are warranted for selecting patients for the best possible management of NAFLD in T2D.